The 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...

The median patient age was 54 years, 77.8% of patients had stage III disease, and 88.6% had serous ovarian cancer. The ...

Oncoinvent Announces Promising Interim Results for Radspherin® as a Potential Treatment for Peritoneal Carcinomatoses ...

Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced an interim data readout of the Phase 1/2a studies of Radspherin® for the tre ...

Although polycythemia vera management remains focused on reducing the risk of thrombotic events, there is growing recognition ...

RAD-18-002 is a Phase 1/2a open-label study designed to select the clinical dose, and evaluate the safety, tolerability, and signal of efficacy of intraperitoneally administered Radspherin® in ...

Dr Chandrashekhar and his team meticulously planned and executed the intricate HIPEC surgery, which involved a combination of cytoreductive surgery and heated chemotherapy, delivered directly to ...

Get Durgabai Deshmukh Renova Cancer Centre News on Telangana Today, Durgabai Deshmukh Renova Cancer Centre latest news, Durgabai Deshmukh Renova Cancer Centre news, | Telangana Today ...

Abiraterone use for prostate cancer can cause mineralocorticoid excess syndrome (MES; eg, hypertension and hypokalemia). Prednisone mitigates these effects; however, the optimal dose level is unclear.

Early detection is critical for the successful treatment of gynaecologic cancers, such as cervical, ovarian, and uterine cancers. Advanced screening methods like Pap smears, HPV testing, and ...

Impact of the Affordable Care Act and Medicaid Expansion Among Patients With HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphomas ...